The Future of Advanced Nuclear Technologies Interdisciplinary Research Team Summaries (2014) / Chapter Skim
Currently Skimming:
IDR Team Summary 1: Identify improvements in technology and other approaches that will ensure the future development and supply of radionuclides and radiopharmaceuticals for diagnostic imaging and therapy.
IDR Team Summary 1: Identify improvements in technology and other approaches that will ensure the future development and supply of radionuclides and radiopharmaceuticals for diagnostic imaging and therapy.
Pages 9-26
The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.
From page 9... ...
and there has been considerable effort to develop a sustainable supply in this country (see American Medical Isotope Production Act of 2012)
|
From page 10... ...
Except for I-124, which can be used as iodide for thyroid studies, all need to be incorporated into complex organic compounds for imaging purposes. For all medical imaging procedures there is a need to minimize the radiation dose received by patients without sacrificing diagnostic accuracy.
|
From page 11... ...
• As optimization of radiation dose in medicine becomes dictum, efforts will be made to use diagnostic nuclear medical studies appropriate to the clinical questions asked. In addition, technologies are, and will be, developed to reduce amounts of administered radioactivity without loss of diagnostic accuracy.
|
From page 12... ...
SNM Position Statement on dose optimization for nuclear medicine and molecular imaging procedures. Society for Nuclear Medicine: June 2012.
|
From page 13... ...
and targeted radiotherapy, which are common in contemporary medicine. The major advantages of using enriched stable isotopes for radioisotope production are that purer, higher specific activity radioisotopes can be produced.
|
From page 14... ...
This tracer is indeed a powerful tool in nuclear medicine, but focusing on this one tracer limits the availability of new tracers for clinical trials, making the approval of potentially beneficial new tracers a problem. The United States needs a decentralized and coordinated infrastructure of cyclotrons to manufacture a variety of radiotracers for clinical use.
|
From page 15... ...
The country needs programs to ignite young people's interest in nuclear science, such as the Department of Energy's recently closed Nuclear Summer School. Universities, professional societies, and government agencies need to work together to develop a curriculum enabling practitioners of all subspecialties relating to nuclear medicine to work together effectively.
|
From page 16... ...
Louis • Izabela Tworowska, RadioMedix Inc.; RITA Foundation Houston • Frank J Wessel, University of California, Irvine • Julianne Wyrick, University of Georgia IDR TEAM SUMMARY -- GROUP 1B Julianne Wyrick, NAKFI Science Writing Scholar University of Georgia IDR Team 1B was asked to identify improvements in technology and other approaches that will ensure the future development and supply of radionuclides and radiopharmaceuticals for diagnostic imaging and therapy.
|
From page 17... ...
Better partnerships among these three entities -- academic institutions, clinics, and companies -- are also needed to ensure the development of useful radionuclide imaging assays. The IDR Team noted that these partnerships should involve the commitment of money by all parties.
|
From page 18... ...
Costs of studying imaging agents could be reduced if researchers did not have to repeat these studies for compounds that have already been studied by other researchers. The IDR Team's strategy for sharing toxicology and pharmacokinetics data is the creation of a database called Free RIDES, an acronym for "Radiopharmaceutical + Imaging Database to Enable Sharing." The idea is based on the way protein sequences are already shared through public databases, such as the RCSB Protein Data Bank (PDB)
|
From page 19... ...
Top-Down Approach The second approach the IDR Team identified for developing useful imaging assays is the top-down approach, as shown in Figure 1. This involves starting with the clinical needs for imaging and then identifying radionuclide imaging agents to meet these needs.
|
From page 20... ...
Team 1B suggested that the panel include physicians, basic scientists, applied imaging scientists, business leaders, patient advocates, and regulatory body representatives. After the expert panel identifies the highest priority disease components, the IDR Team envisions that a funding body, such as the NIH, would develop grants for research of imaging assays addressing these components.
|
From page 21... ...
Though President Obama ratified the American Medical Isotope Production Act in 2013 to protect the interests of nuclear medicine, more emphasis has been placed on phasing out enriched uranium rather than securing and stabilizing the medical isotope market. The IDR Team agreed on four specific challenges that must be addressed to advance next-generation PET radiopharmaceuticals and nuclear science.
|
From page 22... ...
Finally, education initiatives should be implemented to correct public myths connected to the safety of nuclear medicine. The IDR Team ultimately developed a series of directives to tackle each hurdle, which they posited as the framework for a future policy statement to be issued by a major nuclear organization, such as the Society of Nuclear Medicine and Molecular Imaging.
|
From page 23... ...
The decision represented a scary prospect for nuclear medicine, suggesting that heavy investments in the research and development of prospective tools may not be reimbursed at the end of the day. The average cost of inventing and obtaining FDA approval of a new drug is $1.3 billion, according to Eli Lilly, which now owns Amyvid and stands to lose up to $650 million across international markets.
|
From page 24... ...
The goal would be to unify the way scientists design their projects, produce gold standards for radiopharmaceutical validation, and gauge the best endpoints for clinical design. Marquee example: prostate cancer PET imaging agents Prostate cancer was posited as a promising realm for attempting trial harmony.
|
From page 25... ...
Teaching Millennials About Nuclear Medicine Two groups were spotlighted as important targets for education initiatives: young scientists and the general public. The next generation of nuclear medicine scientists No amount of innovation can replace bright minds, and a concern that loomed over the entire conference is the nuclear industry's aging
|
From page 26... ...
North Carolina was suggested as a prime location for the camp, because NC State University runs a research reactor, while the University of North Carolina Chapel Hill has a renowned nuclear medicine program. A new nuclear dictionary for the public Public relations must improve for nuclear medicine, according to the IDR Team.
|
Key Terms
This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More
information on Chapter Skim is available.